A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages

  Sotiriou, Elena ^a   Goussi, Christina ^a   Lallas, Aimilios ^b   Chovarda, Eleni ^a   Apalla, Zoe ^b   Lazaridou, Elisabeth ^a   Ioannides, Demetris ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b State Hospital for Skin and Venereal Diseases   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; QUESTIONNAIRE; RELAPSE; SUPPURATIVE HIDRADENITIS; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860904993     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol. 2009;60:539-561.
2. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985-998.
3. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328-332.
4. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-154.
5. van der Zee HH, Boer J, Prens EP, et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143-147.
6. Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology. 2009;218(2):134-135.
7. Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: A series of 24 patients. Dermatology. 2011;222(4):342-346. Epub 2011 Jul 12.
8. Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol. 2006;31(1):154-155.
9. Matusiak L, Bieniek A, Szepietowski JC. Increased serum timour necrosis factor-α in hidradenitis suppurativa patients: Is there a basis of treatment with anti-tumour Necrosis Factor-α agents? Acta Derm Venreol. 2009;89:601-603.
10. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL- 10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292-1298.
11. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205-217.
12. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg. 2009;13(4):221-225.
13. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56(4):624-628. (Pubitemid 46400174)
14. Delage M, Samimi M, Altan M, et al. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol. 2011;91(2):169-171.
15. van Rappard DC, Leenarts MF, Meijerink-van't Oost L et al. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2011 Jul 14. [Epub ahead of print].
16. Lee RA, Dommasch E, Treat J. et al A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565-573.
17. Sotiriou E, Apalla Z, Ioannides D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol. 2009;89(1):82-83.
18. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726-729. (Pubitemid 43374099)
19. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158(3):567-572. (Pubitemid 351239170)
20. Pelekanou A, Kanni T, Savva A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol. 2010;19(6):538-540.
21. Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J. 2010;16(8):15.
22. Gorovoy I, Berghoff A, Ferris L. Successful treatment of recalcitrant hidradenitis suppurativa with adalimumab. Case Rep Dermatol. 2009;1(1):71-77.
23. Harde V, Mrowietz U. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J Dtsch Dermatol Ges. 2009;7(2):139-141.
24. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis supprativa with adalimumab. J Am Acad Dermatol. 2006;55(1):163-164. (Pubitemid 43867032)
25. Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol. 2009;8(2):181-183.
26. Moul D, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142(9):1110-1112. (Pubitemid 44414393)
27. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145(5):580-584.
28. Sotiriou E, Apalla Z, Vakirlis E, et al. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2009;19(2):180-181.
29. Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49(12):1445-1449.
30. Miller I., Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391-398.
31. Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950-955.
32. Kimball AB, Gu Y, Okun M, et al. Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the pacebo-controlled portion of a phase II, randomized, doubleblind study. P 3340 69. Annual AAD Meeting, New Orleans, Louisiana, February 4-8, 2011.
33. Hurley HJ. Axillary hiperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Roenigk RA, Roenigk HH Jr., editors. Dermatological Surgery: Principles and Practica N.York:Marcel Dekker, 1989, p.735.
34. Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211-213. (Pubitemid 36966545)
35. Sartorius K, Killasli H, Heilborn J, et al. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol. 2010;162:1261-1268.
36. Yazdanyar S, Jemec GB. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis. 2011;24(2):118-123.
37. Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17(5):455-456.